STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS
MICHAEL BAALKANI, M.D. • C14-676 and C14-307

DEPARTMENT OF HEALTH

BOARD OF MEDICAL LICENSURE
AND DISCIPLINE

IN THE MATTER OF:
Michael Baaklini, M.D.
License Number MD07640
BMLD Case Numbers C14-676 and C14-307

CONSENT ORDER

Michael Baaklini, M.D. (hereinafter “Respondent”) is licensed as a physician in Rhode Island. After a review of the above-referenced complaint and accompanying medical records by an investigative committee of the Board of Medical Licensure and Discipline (“Board”), the Board makes the following:

FINDINGS OF FACT

1. Respondent is a licensed physician in the State of Rhode Island and was issued his license on October 4, 1989. He graduated from Ross School of Medicine in 1984. His office is located at Cedarz Medical Center, 812 Metacom Avenue, Bristol, Rhode Island. His primary specialty is Internal Medicine.

2. The Board’s investigative committee members who reviewed this complaint found that Respondent on multiple occasions over a period of several years prescribed Methadone to a patient, who had known poly-substance abuse, outside of a methadone maintenance program; and that
Respondent failed to adequately document in his medical records for this patient his controlled substance prescribing.

3. The investigative committee reviewed several other medical records and interviewed Respondent about his usual approach to prescribing controlled substances. The committee found that the Respondent had not made sufficient use of the Prescription Monitoring Program for high-risk patients due to certain program limitations; Respondent's medical records do not reveal coordination of care for patients who are taking controlled substances from multiple prescribers; Respondent educated his patients as to the risk of taking combinations of various types of controlled substances and/or alcohol, but did not sufficiently document such patient education; and Respondent's controlled substance prescribing is not clearly documented.

4. Based on the facts cited in paragraphs 2 and 3 above, the Board finds Respondent is in civil violation of Rhode Island General Laws §§ 5-37-5.1(19), 5-37-5.1(28) and 21-28-3.04.

Based on the foregoing, the parties agree as follows:

1. Respondent admits to the jurisdiction of the Board.

2. Respondent has reviewed this Consent Order and understands that it is subject to final approval of the Board; and this Consent Order is not binding on Respondent until final ratification by the Board.
3. By presenting this Consent Order to the Board, Respondent hereby acknowledges and waives:
   a. The right to appear personally or by counsel or both before the Board;
   b. The right to produce witnesses and evidence on his behalf at a hearing;
   c. The right to cross examine witnesses;
   d. The right to have subpoenas issued by the Board;
   e. The right to further procedural steps except for those specifically contained herein;
   f. Any and all rights of appeal of this Consent Order; and
   g. Any objection to the fact that this Consent Order will be presented to the Board for consideration and review.

4. Respondent agrees to this Reprimand on his physician license.

5. Respondent agrees to take the Vanderbilt, or other Board-approved, controlled substance prescribing course as well as a Board-approved course in medical records within nine (9) months of ratification of this order.

6. Respondent agrees to pay to the Rhode Island General Treasury an
administrative fee of $1000 within sixty (60) days of ratification of this order.

7. Respondent shall cease to prescribe methadone to any patient for the purpose of methadone maintenance but may continue to prescribe methadone when appropriate for pain management, which shall be documented.

8. Respondent must ensure appropriate and immediate transition of care for existing methadone patients to a proper methadone maintenance treatment program.

9. Respondent must document in any patient’s medical record, whenever prescribing a controlled substance, the name, dose, quantity and indication for such controlled substance. Respondent must educate patients who are taking more than one controlled substance about the risk inherent in doing so, and must educate patients who are taking any controlled substances about the dangers of using alcohol with them.

10. Respondent must create and have patient signatures on pain agreements for any patients taking long-term opioids.

11. Respondent must — prior to prescribing any patient an opioid — use the Prescription Monitoring Program and check a patient’s urine for adherence to the patient’s use of controlled substances at appropriate intervals.
Signed this 13 day of May, 2015.

Michael Baaklini, M.D.

Ratified by the Board of Medical Licensure and Discipline on the 13 day of May, 2015.

Nicole Alexander-Scott, M.D., M.P.H.
Director of Health